SAN

77.13

+3.47%↑

ARGX

729.2

+2.76%↑

SHL.DE

34.85

+2.56%↑

PHIA

22.76

+3.41%↑

FRE

37.2

+1.89%↑

SAN

77.13

+3.47%↑

ARGX

729.2

+2.76%↑

SHL.DE

34.85

+2.56%↑

PHIA

22.76

+3.41%↑

FRE

37.2

+1.89%↑

SAN

77.13

+3.47%↑

ARGX

729.2

+2.76%↑

SHL.DE

34.85

+2.56%↑

PHIA

22.76

+3.41%↑

FRE

37.2

+1.89%↑

SAN

77.13

+3.47%↑

ARGX

729.2

+2.76%↑

SHL.DE

34.85

+2.56%↑

PHIA

22.76

+3.41%↑

FRE

37.2

+1.89%↑

SAN

77.13

+3.47%↑

ARGX

729.2

+2.76%↑

SHL.DE

34.85

+2.56%↑

PHIA

22.76

+3.41%↑

FRE

37.2

+1.89%↑

Home・Aktien・BioMerieux

BioMerieux

Open

BrancheGesundheitswesen

73.7 3.08

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

71.85

Max

73.75

Schlüsselkennzahlen
By Trading Economics
Einkommen	75M 236M
Verkäufe	-18M 2B
KGV Branchendurchschnitt	21.407 49.888
EPS	1.986
Dividendenrendite	1.32
Gewinnspanne	11.663
Angestellte	14,562
EBITDA	200K 476M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+23.02% upside

Dividenden
By Dow Jones
Dividendenrendite Branchendurchschnitt	1.32% 2.38%
Nächstes Ergebnis	28. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-2.7B 8.4B
Vorheriger Eröffnungskurs	70.62
Vorheriger Schlusskurs	73.7

Nachrichtenstimmung

By Acuity

19%

81%

33 / 344 Ranking in Healthcare

BioMerieux Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

BioMerieux Prognose

Kursziel

By TipRanks

23.02% Vorteil

12-Monats-Prognose

Durchschnitt 87.1 EUR 23.02%

Hoch 100 EUR

Tief 71.6 EUR

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für BioMerieux – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

6 ratings

Buy

Halten

Sell

Basierend auf 6 Analysten, die in den letzten 3 Monaten Aktienbewertungen für BioMerieux – Dist abgegeben haben.

Stimmung

By Acuity

33 / 344 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über BioMerieux

bioMérieux S.A. develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemaseproducing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO BACT/ALERT 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction (PCR) system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated Identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL Rapid AST system; ETEST Gradient method on culture media; BIOMERIEUX EPISEQ CS whole genome sequencing solution for epidemiologic monitoring; and VIDASB·R·A·H·M·S PCTTM, a specific marker of severe bacterial infections/sepsis. It also provides Biomérieux vision suite, a software that provides actionable information to support diagnosis and clinical decision making; culture media and associated instruments; ARGENE Monoplex PCR tests; NUCLISENS ranges, a product for automation of the molecular biology laboratory and extraction; EMAG system For DNA and RNA extraction; ESTREAM, an automated preparation station for samples to process PCR tests; GENE-UP and VERIFLOW ranges for detection of microorganisms for the food industry. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.